In the ever-evolving landscape of medical technology, innovation often emerges from the intersection of necessity and expertise. This was the case in 2007 when a team of inventors and scientists at Groningen University, the Netherlands embarked on a mission to address a critical need in the cardiac assist industry. With a steadfast commitment to affordability and efficiency, they set out to develop cutting-edge technology that would not only pulsate but also synchronize seamlessly with the heart’s natural rhythm. This endeavor marked the genesis of PulseCath, a pioneering company driven by the vision of becoming a leader in mechanical circulatory support while ensuring that life-saving solutions remain accessible to all.
PulseCath’s journey began as an incubator company, but it faced financial difficulties. However, the company was able to secure funding from a venture capital firm in the Netherlands. With their support, the company continued its research and development and successfully created the IVAC 3L, a surgical pump for the left ventricle. Later, PulseCath developed the IVAC 2L, a percutaneous pump that transports blood from the ventricle to the ascending aorta. In 2014, PulseCath obtained the CE Marking, allowing it to sell its product in Europe. Although this product received approval, PulseCath decided to conduct clinical studies to demonstrate the effectiveness and advantages of the pulsatile synchronization system. Inearly 2019, PulseCath started selling the product globally and expanded to different regions. Today, the company is registered in over 45 countries and has a strong network of distributors. PulseCath is proud of its progress and performs hundreds cases annually.
PulseCath is making waves in medical technology with its cutting-edge platform, currently undergoing rigorous testing in Germany.
PulseCath is making waves in medical technology with its new ventricle Mechanical circulatory support cutting-edge platform, currently undergoing rigorous testing in Germany. This platform builds on the proven IVAC technology that’s already out there. What’s unique about PulseCath’s approach is how they’ve moved the valve from the catheter into a smart T-shaped housing outside the body, alongside a membrane pump. This combo allows for a flow rate of up to five liters per minute, much more than the two liters per minute offered by IVAC 2L. This is great news for patients dealing with serious heart issues like cardiogenic shock or heart failure.
What sets PulseCath apart is its flexibility. Their platform is driven and compatible with all available intra-aortic balloon driver, offering a synchronized system that can adapt to heart failure levels. Doctors have the freedom to choose from various cannulas for accessing the body, and PulseCath has tested their system with top brands, ensuring top-notch performance. Plus, doctors can tailor how they access the body based on the patient’s needs, whether it’s through a small incision, an open chest, or even directly through the aorta.
PulseCath is also facing challenges in getting the surgeons and cardiologists on board with their technology. CEO Oren Malchin stresses the importance of clinical studies and proper training. That’s why PulseCath has developed an extensive education program, including videos and hands-on training sessions, to make sure medical staff know how to use their device effectively. They’re committed to overcoming these challenges by offering comprehensive training globally throughout the year.
We are focused on expanding our global distribution, generating innovation and new products to broaden the company’s product portfolio to become the world’s circulatory support leader.
PulseCath’s current strategy revolves around teaming up with a major company to leverage its marketing prowess, financial resources, and market influence to establish itself as a leader in the industry. According to Oren Malchin the future trajectory suggests that these big corporations will only strengthen their dominance, potentially becoming the primary channels for widespread technology distribution. However, despite their might, these large players often lag behind in innovation—a gap that smaller companies like PulseCath are well-positioned to fill. PulseCath focuses on the crucial early stages of development, testing, and refining products. Malchin envisions a future with two distinct stages: startups and smaller firms driving innovation and creating novel products, which are then adopted by larger
Looking ahead, Pulsecath is confident in its future prospects, as it expects to expand its market share with its existing and new products. The company aims to enter the US and APAC markets, where there is a high demand for its innovative solutions. Pulsecath also plans to continue developing new technologies that will establish its position as a market leader in the field.
Oren Malchin: A visionary entrepreneur and CEO, driving innovation in the medical technology sector with his strategic leadership at PulseCath
Oren Malchin has a wealth of experience as a CEO in the medical device industry. He is proficient in Marketing Management, Medical Devices, Design Control, Management, and Capital Equipment. He holds a Master of Business Administration (M.B.A.) in Business Administration and Management from the University of Derby, as well as a B.B.A from Northwood
